| A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon TI Verhoef, G Ragia, A de Boer, R Barallon, G Kolovou, V Kolovou, ... New England Journal of Medicine 369 (24), 2304-2312, 2013 | 270 | 2013 |
| Pharmacogenetic‐guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon TI Verhoef, WK Redekop, AK Daly, RMF Van Schie, A De Boer, ... British journal of clinical pharmacology 77 (4), 626-641, 2014 | 220 | 2014 |
| Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down’s syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units LS Chitty, D Wright, M Hill, TI Verhoef, R Daley, C Lewis, S Mason, ... bmj 354, 2016 | 179 | 2016 |
| Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design RMF Van Schie, MIA Wadelius, F Kamali, AK Daly, VG Manolopoulos, ... Pharmacogenomics 10 (10), 1687-1695, 2009 | 170 | 2009 |
| Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data RMF Van Schie, JAM Wessels, S le Cessie, A de Boer, T Schalekamp, ... European heart journal 32 (15), 1909-1917, 2011 | 126 | 2011 |
| Non‐invasive prenatal diagnosis for cystic fibrosis: detection of paternal mutations, exploration of patient preferences and cost analysis M Hill, P Twiss, TI Verhoef, S Drury, F McKay, S Mason, L Jenkins, ... Prenatal diagnosis 35 (10), 950-958, 2015 | 105 | 2015 |
| Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings TI Verhoef, WK Redekop, F Hasrat, A de Boer, AH Maitland-van der Zee American Journal of Cardiovascular Drugs 14, 451-462, 2014 | 68 | 2014 |
| Non‐invasive prenatal diagnosis (NIPD) for single gene disorders: cost analysis of NIPD and invasive testing pathways TI Verhoef, M Hill, S Drury, S Mason, L Jenkins, S Morris, LS Chitty Prenatal diagnosis 36 (7), 636-642, 2016 | 67 | 2016 |
| Evaluation of Array Comparative genomic Hybridisation in prenatal diagnosis of fetal anomalies: a multicentre cohort study with cost analysis and assessment of patient, health … SC Robson, LS Chitty, S Morris, T Verhoef, G Ambler, DG Wellesley, ... Efficacy and Mechanism Evaluation 4 (1), 1-104, 2017 | 55 | 2017 |
| Does use of point-of-care testing improve cost-effectiveness of the NHS Health Check programme in the primary care setting? A cost-minimisation analysis A El-Osta, M Woringer, E Pizzo, T Verhoef, C Dickie, MZ Ni, JR Huddy, ... BMJ open 7 (8), e015494, 2017 | 49 | 2017 |
| Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden TI Verhoef, WK Redekop, S Langenskiold, F Kamali, M Wadelius, ... The pharmacogenomics journal 16 (5), 478-484, 2016 | 49 | 2016 |
| Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes R Howard, JBS Leathart, DJ French, E Krishan, H Kohnke, M Wadelius, ... Clinica Chimica Acta 412 (23-24), 2063-2069, 2011 | 47 | 2011 |
| Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single‐Patient Data Meta‐Analysis in More Than 15,000 Individuals E Danese, S Raimondi, M Montagnana, A Tagetti, T Langaee, P Borgiani, ... Clinical Pharmacology & Therapeutics 105 (6), 1477-1491, 2019 | 41 | 2019 |
| Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants CL Marvig, TI Verhoef, A De Boer, F Kamali, K Redekop, M Pirmohamed, ... Thrombosis Research 136 (1), 69-75, 2015 | 38 | 2015 |
| Long‐term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users TI Verhoef, WK Redekop, MM Buikema, T Schalekamp, ... Journal of thrombosis and haemostasis 10 (4), 606-614, 2012 | 34 | 2012 |
| Cost‐effectiveness and pricing of antibacterial drugs TI Verhoef, S Morris Chemical biology & drug design 85 (1), 4-13, 2015 | 32 | 2015 |
| A systematic review of cost–effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives TI Verhoef, WK Redekop, J Darba, M Geitona, DA Hughes, U Siebert, ... Pharmacogenomics 11 (7), 989-1002, 2010 | 30 | 2010 |
| Cost–effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation TI Verhoef, WK Redekop, DL Veenstra, R Thariani, PA Beltman, ... Pharmacogenomics 14 (8), 869-883, 2013 | 28 | 2013 |
| Cost-effectiveness of a domestic violence and abuse training and support programme in primary care in the real world: updated modelling based on an MRC phase IV observational … EC Barbosa, TI Verhoef, S Morris, F Solmi, M Johnson, A Sohal, ... BMJ open 8 (8), e021256, 2018 | 25 | 2018 |
| Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs TI Verhoef, WK Redekop, RMF Van Schie, S Bayat, AK Daly, M Geitona, ... Pharmacogenomics 13 (12), 1405-1417, 2012 | 24 | 2012 |
